Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. The Company markets IMBRUVICA in the United States for four United States. Food and Drug Administration (FDA) approved indications for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy, and all lines of Waldenstrom's macroglobulinemia (WM). It is also pursuing the development of IMBRUVICA for Graft versus host disease (GvHD). In addition, it has a pre-clinical testing program underway to develop inhibitors of BTK for inflammatory and autoimmune diseases.
Parent Company
Sunnyvale, US
Pharmacyclics was founded in 1991 and is headquartered in Sunnyvale, US

Pharmacyclics Office Locations

Pharmacyclics has offices in Sunnyvale, South San Francisco, Schaffhausen, Shanghai
Sunnyvale, US
Shanghai, CN
Schaffhausen, CH
South San Francisco, US

Pharmacyclics Metrics

Pharmacyclics Summary

Founding Date

Pharmacyclics is a subsidiary of AbbVie

Pharmacyclics Financials

We estimate that Pharmacyclics's revenue is $729.7 m in FY, 2014 which is a 180.5% increase from the previous period.
FY, 2013FY, 2014


$260.2 m$729.7 m

Revenue growth, %


Gross profit

$256.7 m$689.3 m

Operating expense total

$158.7 m$566.9 m


$97.9 m$122.4 m

Net Income

$67 m$86.1 m

Operating cash flow

$316.5 m$221.1 m

Pharmacyclics Online Presence

Pharmacyclics Company Life

You may also be interested in